Comorbidities and hematopoietic cell transplantation outcomes

Area of Science:

• Hematology
• Transplantation Medicine
• Oncology

Background:

• Allogeneic hematopoietic cell transplantation (allo-HCT) offers curative potential for hematological diseases.
• Reduced-intensity conditioning regimens expanded allo-HCT eligibility but rely heavily on graft-versus-tumor effects.
• Both conditioning approaches carry risks of organ toxicities and graft-versus-host disease, leading to significant non-relapse mortality.

Purpose of the Study:

• To highlight the critical need for optimized pre-transplant risk assessment in allo-HCT.
• To introduce and emphasize the utility of the HCT-comorbidity index (HCT-CI) in predicting transplant outcomes.
• To discuss the integration of HCT-CI with other risk factors for refined patient stratification.

Main Methods:

• Review of existing literature on HCT-CI and its prognostic value.
• Comparison of HCT-CI with non-HCT-specific indices for predicting morbidity and mortality.
• Discussion of ongoing efforts in prospective validation and refinement of HCT-CI.

Main Results:

• The HCT-comorbidity index (HCT-CI) demonstrates superior prediction of HCT-related morbidity and mortality compared to other indices.
• Pre-transplant single-organ comorbidities traditionally predict post-HCT organ toxicity.
• HCT-CI effectively captures multiple-organ comorbidities, enhancing risk stratification.

Conclusions:

• The HCT-CI is a validated tool for improving risk assessment and decision-making in allo-HCT.
• Further research aims to prospectively validate and enhance the applicability of the HCT-CI.
• Understanding comorbidity impact may lead to novel interventions to reduce allo-HCT mortality.